Clearmind Secures Manufacturing and Distribution for Alcohol Substitute
Ticker: CMND · Form: 6-K · Filed: Jul 19, 2024 · CIK: 1892500
Sentiment: neutral
Topics: product-launch, distribution, manufacturing
TL;DR
Clearmind is lining up makers and sellers for their booze-free drink. Big step to market!
AI Summary
Clearmind Medicine Inc. announced on July 19, 2024, that it has signed an agreement to source manufacturers and distributors for its alcohol substitute beverage product. This agreement is a key step in bringing their innovative product to market.
Why It Matters
This move by Clearmind Medicine Inc. is significant as it paves the way for the commercialization of their novel alcohol substitute beverage, potentially impacting the beverage and wellness markets.
Risk Assessment
Risk Level: medium — The company is still in the process of securing manufacturing and distribution, indicating that the product's market entry and success are not yet guaranteed.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- July 19, 2024 (date) — Announcement Date
FAQ
What is the specific nature of the agreement Clearmind Medicine Inc. has signed?
Clearmind Medicine Inc. has signed an agreement to source manufacturers and distributors for its alcohol substitute beverage product.
When was this agreement announced?
The agreement was announced on July 19, 2024.
What is the product Clearmind Medicine Inc. is preparing to launch?
Clearmind Medicine Inc. is preparing to launch an alcohol substitute beverage product.
What is the company's filing number with the SEC?
Clearmind Medicine Inc.'s SEC file number is 001-41557.
Which form is Clearmind Medicine Inc. filing?
Clearmind Medicine Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 274 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-07-19 16:01:11
Filing Documents
- ea0209703-6k_clearmind.htm (6-K) — 11KB
- ea020970301ex99-1_clearmind.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-062989.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: July 19, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3